Reaction
Latent Tuberculosis reporting signals
As of the last recalculation, Latent Tuberculosis appears in 2,061 FAERS reports alongside 36 co-occurring drug terms. The strongest observed disproportionality signal is ISONIAZID (PRR 53.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Isoniazid | 82 | 53.2 | 53.5 |
| Rifampin | 64 | 45.7 | 45.9 |
| Ustekinumab | 167 | 17.8 | 17.9 |
| Theophylline | 15 | 13.3 | 13.3 |
| Adalimumab-Fkjp | 59 | 13.2 | 13.2 |
| Adalimumab-Aaty | 60 | 13.2 | 13.2 |
| Theophylline Anhydrous | 16 | 13.1 | 13.1 |
| Adalimumab-Adaz | 61 | 12.0 | 12.0 |
| Terbinafine Hydrochloride | 10 | 11.4 | 11.4 |
| Hydrocortisone Sodium Succinate | 10 | 10.8 | 10.8 |
| Risankizumab-Rzaa | 81 | 10.4 | 10.4 |
| Golimumab | 80 | 9.8 | 9.8 |
| Guselkumab | 33 | 9.5 | 9.5 |
| Rifampicin | 9 | 9.0 | 9.0 |
| Leflunomide | 89 | 8.9 | 8.9 |
| Methotrexate | 313 | 8.7 | 8.7 |
| Methotrexate Sodium | 351 | 8.6 | 8.6 |
| Hydroxychloroquine | 61 | 8.5 | 8.5 |
| Infliximab | 168 | 8.4 | 8.4 |
| Certolizumab Pegol | 88 | 7.9 | 7.9 |
| Basiliximab | 9 | 7.8 | 7.8 |
| Sulfasalazine | 58 | 7.7 | 7.7 |
| Vedolizumab | 54 | 6.5 | 6.5 |
| Secukinumab | 99 | 6.5 | 6.5 |
| Baricitinib | 6 | 6.3 | 6.3 |
| Remdesivir | 8 | 6.1 | 6.1 |
| Cetirizine Hydrochloride Allergy | 18 | 6.0 | 6.0 |
| Cetirizine Hydrochloride Tablets | 18 | 6.0 | 6.0 |
| Tofacitinib | 94 | 5.3 | 5.3 |
| Ixekizumab | 19 | 5.2 | 5.2 |
| Upadacitinib | 41 | 5.2 | 5.2 |
| Adalimumab | 307 | 5.0 | 5.0 |
| Bimekizumab | 10 | 4.8 | 4.8 |
| Etanercept | 253 | 4.7 | 4.7 |
| Apremilast | 47 | 3.3 | 3.3 |
| Natalizumab | 58 | 3.3 | 3.3 |